Chronic Kidney Disease With and Without HemodialysisArrhythmiaNCT07640919
Patterns of Cardiac Arrhythmia in Patients With Chronic Kidney Disease
An observational study of Chronic Kidney Disease With and Without Hemodialysis, run by Sohag University at 1 site in Egypt.
Trial summary
Cardiovascular diseases remain the primary leading cause of death in patients on maintenance hemodialysis accounting for nearly 41% of deaths. Chronic kidney disease is associated with an excess of acquired arrhythmia of multiple types, and atrial fibrillation in particular. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Kidney Disease With and Without Hemodialysis
- How many people
- 200 participants
- Where
- 1 siteEgypt
- Study dates
- 20 Jul 2026to 20 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with chronic kidney disease at hemodialysis unit and outpatient nephrology clinic at Sohag university hospitals
Who may be able to join
- Patients with CKD (no intercurrent illness or uremic symptoms, and not hospitalized in the previous 3 months) with renal replacement therapy on maintenance HD (three times/week for at least three months) or without renal replacement therapy, aged 18 or above.
Who cannot join
- Patients aged <18 years old.
- Patients on drugs that are known to prolong the QT interval (e.g., antibiotics as clarithromycin, antifungal as fluconazole, antiarrhythmics as amiodarone, antipsychotic as chlorpromazine)
- Patients with structural heart diseases (e.g.,significant valvular lesions )
- Patients with impaired left ventricular systolic functions (defined as EF< 50%
- Patients with malignancy, severe infection or sepsis.
- Patients with major bleeding.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Sohag university hospitals
Sohag, ElKholy, 82714
Emad Ahmad Mohamad, Associate professor, 00201101779988, Emadabokhabar@gmail.com
Noher Mohamad Abass, Associate professor, 00201224921932, nohermohamed3581@gmail.com
About this study
Official title: Patterns of Cardiac Arrhythmia In Patients With Chronic Kidney Disease at Sohag University Hospitals
Cardiovascular diseases remain the primary leading cause of death in patients on maintenance hemodialysis accounting for nearly 41% of deaths.
Chronic kidney disease is associated with an excess of acquired arrhythmia of multiple types, and atrial fibrillation in particular.
Sudden cardiac death is also more common in chronic kidney disease and accounts for around one- quarter of deaths in dialysis patients.
The aim of the study is to evaluate the incidence, describe the patterns of cardiac arrhythmia and to determine the factors predisposing to cardiac arrhythmia in patients with chronic kidney disease with or without hemodialysis.
Read the detailed description
After obtaining written, informed consents, individuals are subjected to thorough clinical evaluation (age, sex, history of hypertension (HTN) or diabetes mellitus (DM)) and laboratory tests including complete blood count, urea, creatinine, glomerular filtration rate (eGFR) (calculated by CKD-EPI equation) , serum potassium, magnesium, calcium, phosphorus, parathyroid hormone (PTH), iron and total iron binding capacity (TIBC).
Twelve-lead ECG is performed and all ECGs are reviewed for the following parameters: heart rhythm, heart rate, frontal axis, P wave, PR interval, QRS duration, pathological Q wave, fragmented QRS morphology, ST-segment deviation, QT interval and T wave abnormality.
- Keywords
- chronic kidney disease (CKD), cardiac arrhythmia, atrial fibrillation (AF)
- Medical subject headings
- Renal Insufficiency, Chronic, Arrhythmias, Cardiac, Atrial Fibrillation
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection of changes (already exsited) in heart rate (measured in beats/ minutes) and corrected QT interval (measured in milliseconds) from normal limits in patients with chronic kidney disease.
Twelve-lead ECG is performed and all ECGs are reviewed for the following parameters:
- heart rate (measured by beats/minutes) normal limit: 60 - 100 b/m
- corrected QT interval (measured in milliseconds) normal limit: 330 - 440 ms in males and 330 - 450 in female
Measured: Health survey distributed during 4 months to determine how many patients with chronic kidney disease have cardiac arrhythmia in hemodialysis unit and outpatient nephrology clinic at sohag university hospitals
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2026
- Study start20 Jul 2026 (estimated)
- Primary completion20 Dec 2026 (estimated)
- Study completion20 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney Disease With and Without HemodialysisStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Magy Mogahed Mounir, Sohag University
- Investigators
- Emad Ahmad Mohamad, Associate professor, Study director, Faculty of medicine, Sohag university, Internal medicine department
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07640919
- Sponsor's protocol ID
- Soh-Med-26-5-5MS
- Acronym
- Arrhythmia
- Status last verified
- Jun 2026
- First submitted
- 2 Jun 2026
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patterns of Cardiac Arrhythmia In Patients With Chronic Kidney Disease at Sohag University Hospitals
- ClinicalTrials.gov ID
- NCT07640919
- Acronym / sponsor ID
- Arrhythmia / Soh-Med-26-5-5MS
- Keywords
- chronic kidney disease (CKD), cardiac arrhythmia, atrial fibrillation (AF)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 20 Jul 2026 (estimated)
- Primary completion
- 20 Dec 2026 (estimated)
- Study completion
- 20 Jan 2027 (estimated)
- First posted
- 11 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiovascular diseases remain the primary leading cause of death in patients on maintenance hemodialysis accounting for nearly 41% of deaths.
Chronic kidney disease is associated with an excess of acquired arrhythmia of multiple types, and atrial fibrillation in particular.
Sudden cardiac death is also more common in chronic kidney disease and accounts for around one- quarter of deaths in dialysis patients.
The aim of the study is to evaluate the incidence, describe the patterns of cardiac arrhythmia and to determine the factors predisposing to cardiac arrhythmia in patients with chronic kidney disease with or without hemodialysis.
Detailed description
After obtaining written, informed consents, individuals are subjected to thorough clinical evaluation (age, sex, history of hypertension (HTN) or diabetes mellitus (DM)) and laboratory tests including complete blood count, urea, creatinine, glomerular filtration rate (eGFR) (calculated by CKD-EPI equation) , serum potassium, magnesium, calcium, phosphorus, parathyroid hormone (PTH), iron and total iron binding capacity (TIBC).
Twelve-lead ECG is performed and all ECGs are reviewed for the following parameters: heart rhythm, heart rate, frontal axis, P wave, PR interval, QRS duration, pathological Q wave, fragmented QRS morphology, ST-segment deviation, QT interval and T wave abnormality.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with chronic kidney disease at hemodialysis unit and outpatient nephrology clinic at Sohag university hospitals
Key inclusion criteria (1 listed)
- Patients with CKD (no intercurrent illness or uremic symptoms, and not hospitalized in the previous 3 months) with renal replacement therapy on maintenance HD (three times/week for at least three months) or without renal replacement therapy, aged 18 or above.
Key exclusion criteria (6 listed)
- Patients aged <18 years old.
- Patients on drugs that are known to prolong the QT interval (e.g., antibiotics as clarithromycin, antifungal as fluconazole, antiarrhythmics as amiodarone, antipsychotic as chlorpromazine)
- Patients with structural heart diseases (e.g.,significant valvular lesions )
- Patients with impaired left ventricular systolic functions (defined as EF< 50%
- Patients with malignancy, severe infection or sepsis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Detection of changes (already exsited) in heart rate (measured in beats/ minutes) and corrected QT interval (measured in milliseconds) from normal limits in patients with chronic kidney disease.
Time frame: Health survey distributed during 4 months to determine how many patients with chronic kidney disease have cardiac arrhythmia in hemodialysis unit and outpatient nephrology clinic at sohag university hospitals
Twelve-lead ECG is performed and all ECGs are reviewed for the following parameters: * heart rate (measured by beats/minutes) normal limit: 60 - 100 b/m * corrected QT interval (measured in milliseconds) normal limit: 330 - 440 ms in males and 330 - 450 in female
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Kidney Disease With and Without Hemodialysis
Not yet recruitingPhase 1
Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis
End-Stage Kidney Disease (ESKD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Emad Ahmad Mohamad, Associate professor study director
Faculty of medicine, Sohag university, Internal medicine department
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Disease With and Without Hemodialysis, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Magi Mogahed Mounir, Resident doctor (00201276347105, magi.mogahed@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection of changes (already exsited) in heart rate (measured in beats/ minutes) and corrected QT interval (measured in milliseconds) from normal limits in patients with chronic kidney disease. (time frame: Health survey distributed during 4 months to determine how many patients with chronic kidney disease have cardiac arrhythmia in hemodialysis unit and outpatient nephrology clinic at sohag university hospitals). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026; AzTrials last refreshed its copy on 8 Nov 2026.